# GPT 5.2 Review - Reviewer 3/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-23T22:11:27.056919
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_02642578d9af132c006973e357c78c81968b54c2fe88e365e6
**Tokens:** 9734 in / 5708 out
**Response SHA256:** 11a5abf0c84b04e6

---

## Referee Report (Top General-Interest / AEJ:EP Standard)

### Summary
The paper asks an important policy question—whether PDMP mandatory-query mandates reduce opioid overdose mortality—and applies staggered-adoption DiD methods to CDC VSRR mortality data (2015–2020). The headline finding is “null”: TWFE implies +2.0% (SE 5.8%), Sun–Abraham ATT −2.5% (SE 2.8%). However, the design is severely constrained by outcome data beginning in 2015, leaving early adopters always-treated, reducing usable cohorts, and producing evidence of differential pre-trends (event-time −3 significant). As currently written, the paper reads like a transparent *methods exercise* documenting infeasibility/fragility rather than a publishable causal evaluation for a top journal.

Below I separate fixable format issues from fundamental identification and inference concerns.

---

# 1. FORMAT CHECK

### Length
- **Fails top-journal norm.** The manuscript appears to be **~19 pages total** including figures and references (pages numbered through 19 in the provided version). That is **below the requested 25+ pages** (excluding references/appendix) and below typical AER/QJE/JPE/ReStud/Ecta expectations for a full empirical paper.

### References / coverage
- **Not adequate for a top field or general-interest outlet.** The reference list is very short (roughly ~7 items; p. 18–19) and omits several foundational DiD and PDMP policy papers (details in Section 4 below). The current bibliography is not commensurate with the paper’s claims of methodological contribution.

### Prose vs bullets
- Mostly paragraph-form in Sections 1–4, but the **Discussion/Conclusion includes bullet-point style enumeration** (Section 5, p. 15–16). Bullets are not inherently disallowed, but in top journals the **main contribution and interpretation should be written as full prose** with developed paragraphs.

### Section depth (3+ substantive paragraphs each)
- **Introduction (p. 2–3):** ~3–4 paragraphs; acceptable.
- **Data (p. 3–7):** substantive; acceptable.
- **Empirical strategy (p. 7–9):** acceptable.
- **Results (p. 9–15):** borderline; much of it is descriptive plus a single main table; needs deeper engagement with mechanisms, magnitudes, and robustness.
- **Discussion (p. 15–17):** too short and partly bulletized; needs expansion.

### Figures
- Figures shown (event study; map; cohort trends) have axes and visible data. **However:**
  - The event-study figure (p. 19 / Figure 1) needs clearer axis labels and scaling; the y-axis units (“effect on log deaths”) are non-intuitive without translating to percent effects.
  - Figure notes should define the normalization and sample more prominently.
  - The map figure (Figure 2, p. 13–14) is visually acceptable but not publication-quality (legend/contrast and readability).

### Tables
- Tables contain real numbers (Table 1–3). No placeholders. This is fine.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors reported?
- **Pass** for the main regressions: Table 3 reports SEs in parentheses (p. 10–11). Event-study coefficients also report SEs in text (p. 11–12).

### (b) Significance testing shown?
- **Partial pass**: Table 3 uses conventional reporting (SEs, stars note); the text reports p-values for key coefficients. However, not all presented estimates in figures are accompanied by a table of underlying coefficients/p-values.

### (c) 95% confidence intervals for main results?
- **Fail (as written).** You mention 95% CIs in the event-study figure note, but **Table 3 does not report 95% CIs**, and the narrative emphasizes p-values rather than interval estimates.
  - This is fixable: report CIs in Table 3 and in the abstract.
  - For example, implied approximate 95% CIs:
    - TWFE: 0.020 ± 1.96·0.058 ≈ **[−0.094, 0.134]** (≈ −9.4% to +13.4%)
    - Sun–Abraham: −0.025 ± 1.96·0.028 ≈ **[−0.080, 0.030]** (≈ −8.0% to +3.0%)

### (d) Sample sizes N reported?
- **Pass**: Table 3 reports observations and jurisdictions; Table 1 reports N for pre/post subsets.

### (e) DiD with staggered adoption
- **Mixed; not acceptable for a top journal in current form.**
  - You do implement **Sun–Abraham** (good), and you discuss TWFE heterogeneity problems (p. 8–9).
  - But the paper still places substantial weight on a **TWFE** estimate that (i) includes always-treated early adopters in the sample window and (ii) may use already-treated units as controls mechanically through FE structure.
  - You do not provide a **Goodman–Bacon decomposition** to show what comparisons are identifying TWFE here, nor do you provide a “stacked DiD” or Callaway–Sant’Anna estimator as a primary estimand.
  - Given the very short panel and the pretrend violation (p. 11–12), the DiD design is not credible enough to support policy conclusions.

### (f) RDD requirements
- Not applicable (no RDD). Fine.

### Additional inference concerns not adequately addressed
1. **Few clusters and short T**: clustering at the state level with ~27–41 clusters (depending on spec) is not automatically fatal, but top journals increasingly expect robustness via **wild cluster bootstrap** (or randomization inference) especially when key results are null/fragile.
2. **Outcome modeling**: log(Y+1) for death counts is common but not ideal. A top-journal paper should show robustness using:
   - log(rate) with population offsets,
   - Poisson/PPML with FE (and exposure), or
   - negative binomial (with careful discussion).
3. **Multiple-testing / pretrend testing**: you highlight a significant lead (t = −3, p = 0.007; p. 11–12). A top-journal treatment would discuss Roth (2022) / pretrend sensitivity and whether that is a false discovery among many leads.

**Bottom line on methodology:** you have basic inference reporting, but the design does not clear the credibility bar for a top journal because identification is weak and diagnostics indicate violations.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
- **Not credible enough for causal claims.** The paper’s own evidence shows:
  - **Early adopters are always-treated** in 2015–2020 (p. 4–5), removing pre-treatment variation for precisely the states likely most informative about prescription-opioid-era mortality.
  - **Event study shows differential pre-trends** (t = −3 significant; p. 11–12), violating parallel trends.
  - Policy adoption is plausibly **endogenous to crisis severity** (acknowledged, p. 15–16).

Given these, the correct interpretation is closer to: *“With these data and this research design, we cannot credibly estimate the causal effect.”* That may be a useful methodological note, but it is not framed or executed as a publishable contribution for AER/QJE/JPE/ReStud/Ecta/AEJ:EP.

### Key assumptions discussed?
- You discuss parallel trends and TWFE heterogeneity issues (p. 8–9). That is good.
- But you do not provide a convincing strategy to restore credibility when assumptions fail (e.g., alternative control construction, covariate adjustments with justification, or design-based approaches).

### Placebos and robustness
- Robustness is thin (Section 4.5, p. 15: opioid share). A top outlet would expect, at minimum:
  1. **Alternative outcome definitions**: prescription-opioid deaths vs synthetic-opioid deaths vs heroin, to test substitution (you mention it, p. 16, but do not estimate it).
  2. **Alternative treatment coding**: effective date vs enactment; mid-year implementation using monthly data; intensity of mandate (exemptions, enforcement).
  3. **Alternative estimators**: Callaway–Sant’Anna; stacked DiD; Borusyak–Jaravel–Spiess imputation; de Chaisemartin–D’Haultfoeuille.
  4. **Policy controls**: naloxone access laws, pain clinic laws, pill mill enforcement, Medicaid expansion, marijuana legalization, etc., at least as sensitivity checks (with appropriate caution about “bad controls”).
  5. **Donut / anticipation checks**: exclude adoption year; show sensitivity.
  6. **Weighting**: population-weighted vs unweighted results (mortality counts should not treat WY and CA equally without discussion).

### Do conclusions follow from evidence?
- The conclusion currently risks over-interpreting “null effects.” The paper does acknowledge identification problems (p. 15–16), but the abstract still leads with “we find no statistically significant effect,” which is not the same as “no effect.”
- For a top journal, you must more clearly distinguish:
  - “estimated ATT is small” vs
  - “data/design too weak to learn the effect.”

### Limitations discussed?
- Yes (p. 16–17), especially partial-year coding and lack of pre-periods. This is a strength; however, the limitations are so central that they undermine the paper’s contribution unless you change the design/data.

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

## (A) Foundational staggered-adoption DiD methods missing
You cite Goodman-Bacon (2021) and Sun–Abraham (2021). For a top-journal-ready draft you also need (at least) the following:

1) **Callaway & Sant’Anna (2021)** — group-time ATT estimator with never-treated / not-yet-treated comparisons; canonical alternative to TWFE.
```bibtex
@article{CallawaySantAnna2021,
  author  = {Callaway, Brantly and Sant'Anna, Pedro H. C.},
  title   = {Difference-in-Differences with Multiple Time Periods},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {200--230}
}
```

2) **Borusyak, Jaravel & Spiess (2021)** — imputation estimator; often performs well with staggered adoption and short panels.
```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year    = {2021}
}
```
*(If you prefer only peer-reviewed citations, cite later journal versions if/when available; but top journals routinely accept this working-paper citation given prominence.)*

3) **de Chaisemartin & D’Haultfoeuille (2020/2022)** — DID with heterogeneous effects; alternative robust estimators and diagnostics.
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultfoeuille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

4) **Roth (2022)** — pretrend testing, power, and sensitivity; directly relevant given your significant lead at t = −3.
```bibtex
@article{Roth2022,
  author  = {Roth, Jonathan},
  title   = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year    = {2022},
  volume  = {4},
  number  = {3},
  pages   = {305--322}
}
```

5) **Cengiz et al. (2019)** — “stacked DiD” approach widely used in policy evaluation when adoption timing varies.
```bibtex
@article{CengizEtAl2019,
  author  = {Cengiz, Doruk and Dube, Arindrajit and Lindner, Attila and Zipperer, Ben},
  title   = {The Effect of Minimum Wages on Low-Wage Jobs},
  journal = {Quarterly Journal of Economics},
  year    = {2019},
  volume  = {134},
  number  = {3},
  pages   = {1405--1454}
}
```

## (B) PDMP / opioid policy empirical literature missing
Your current policy citations are sparse (Patrick et al. 2016; Buchmueller & Carey 2018; a few working papers). A top-journal draft should engage a broader set, including substitution to illicit opioids and related opioid policies.

Examples to consider (you should choose the most relevant and accurate to your claims/data):

1) **Dowell, Haegerich & Chou (2016)** (CDC guideline) for institutional context and timing (not economics, but policy backdrop is central).
```bibtex
@article{DowellHaegerichChou2016,
  author  = {Dowell, Deborah and Haegerich, Tamara M. and Chou, Roger},
  title   = {CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016},
  journal = {MMWR Recommendations and Reports},
  year    = {2016},
  volume  = {65},
  number  = {1},
  pages   = {1--49}
}
```

2) **Alpert, Powell & Pacula (2018)** on fentanyl shocks/substitution (helps interpret why PDMP may not reduce total opioid deaths post-2015).
```bibtex
@article{AlpertPowellPacula2018,
  author  = {Alpert, Abby and Powell, David and Pacula, Rosalie Liccardo},
  title   = {Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids},
  journal = {American Economic Journal: Economic Policy},
  year    = {2018},
  volume  = {10},
  number  = {4},
  pages   = {1--35}
}
```

3) **Currie, Jin & Schnell (2018)** (opioid supply/prescribing; depending on exact focus you may cite related Currie work).
```bibtex
@article{CurrieJinSchnell2018,
  author  = {Currie, Janet and Jin, Jonah and Schnell, Molly},
  title   = {U.S. Employment and Opioids: Is There a Connection?},
  journal = {Brookings Papers on Economic Activity},
  year    = {2018},
  pages   = {253--280}
}
```
*(This is less directly PDMP but relevant for opioid crisis economics; you should add more PDMP-specific work too.)*

4) Strongly consider citing a **systematic review** or multi-policy evaluation paper in health economics / policy (e.g., on naloxone laws, pill mill laws, pain clinic laws) to avoid evaluating PDMP in isolation.

**Why these are relevant:** Your null results likely reflect the post-2015 shift toward fentanyl and polysubstance mortality and/or substitution away from prescription opioids. Without engaging this literature, readers cannot interpret what “no effect on opioid deaths” means in the contemporary era.

---

# 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- Mostly prose, but **Section 5 (p. 15–16) uses a numbered list** for the “main findings.” For top journals, convert to **full paragraphs** with interpretation, not just enumeration.

### (b) Narrative flow
- The paper’s narrative is currently: “We ran modern DiD; estimates are null; pretrends fail; data limitations.” That is not yet a compelling arc for a general-interest journal.
- If the *true contribution* is “policy evaluation is infeasible with limited pre-periods and endogenous adoption,” then the introduction should be reframed to foreground that contribution and connect to a broader identification/design message.

### (c) Sentence quality
- Generally clear and non-verbose. However, the writing at times reads like a project memo: many sentences start with “We” and emphasize process rather than insight. Top journals expect more synthesis and interpretation.

### (d) Accessibility / intuition
- You provide some intuition about TWFE pitfalls (p. 8–9). Good.
- You should do more to translate log-point estimates into **lives** (or deaths per 100k) and to explain why the estimated effects could plausibly be zero (mechanisms, substitution, enforcement).

### (e) Figures/tables as stand-alone objects
- Improve titles/notes so each figure is interpretable without reading the main text:
  - define treatment, sample restrictions, normalization, and key takeaway in the note;
  - add a table for event-study coefficients.

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE THIS PUBLISHABLE)

## A. Data and timing: move to monthly outcomes and correct exposure coding
Your own limitation (p. 16) is first-order: coding “treated for the whole year” when laws start in September/December will **attenuate effects mechanically**. Since VSRR is monthly, the most compelling improvement is:
- Build a **monthly panel** (2015–2020), use **event time in months**, and code treatment precisely by effective date.
- Aggregate to year only as a robustness check.

## B. Change the estimand and design: from “TWFE + SA” to a design-first approach
Given the severe pretrend issues, you need a strategy beyond “run SA and report pretrend failure.”

Concrete options:
1. **Callaway–Sant’Anna (2021)** with explicit group-time ATTs; show which cohorts identify what.
2. **Stacked DiD** (cohort-by-cohort) with matched windows around adoption; never-treated as controls; exclude already-treated.
3. **Synthetic control / augmented synthetic control** for selected adopters with good pre-period fit (even with 2015 start, you may have 12–24 monthly pre-periods for 2017–2020 adopters).
4. If claiming evaluation is fundamentally hard, reposition the paper as a **diagnostic paper**: quantify how much identifying variation is lost due to always-treated cohorts, missing states, and partial-year coding. That can be publishable *if framed as a general lesson* and executed rigorously.

## C. Outcomes: separate opioid categories to test substitution hypotheses
You define opioids as T40.0–T40.4, T40.6 (p. 3–4). But policy-relevant substitution is between:
- prescription opioids (natural/semi-synthetic, methadone) vs
- heroin vs
- synthetic opioids (fentanyl).

Estimate category-specific mortality. A plausible pattern is: PDMP reduces prescription-opioid deaths but increases fentanyl/heroin deaths, yielding null net opioid effect. Without this decomposition, the null is hard to interpret.

## D. Controls and competing policies (with caution)
At least demonstrate robustness to adding controls for:
- naloxone access laws,
- pill mill/pain clinic laws,
- Medicaid expansion,
- marijuana legalization,
- Good Samaritan laws.

You must be careful about post-treatment bias; treat these as sensitivity exercises, not definitive.

## E. Inference upgrades
- Use **wild cluster bootstrap** p-values / CIs (state-level clusters; small samples).
- Report **uniform confidence bands** for event studies (or at least discuss multiple comparisons).

## F. Clarify treatment definition and misclassification risk
You code several large jurisdictions as never-treated due to exemptions (e.g., Michigan; California; p. 6). This may create a “control group” that is partly treated. You should:
- show results under alternative codings (broad vs strict mandate definitions),
- treat MI/CA as separate category (“partial mandate”) rather than “never,”
- test sensitivity of results to excluding each never-treated state (leave-one-out), especially CA which heavily influences aggregate mortality.

## G. Reframe the contribution
Right now the contribution is presented as “PDMP mandates do not reduce opioid deaths,” but the internal evidence is closer to “we cannot credibly estimate the effect with these data.” For a top journal, pick one:

1) **Causal claim paper**: requires a stronger design/data expansion to restore credibility.
2) **Research design / measurement paper**: requires broader generalization, deeper diagnostics, and a clearer methodological lesson beyond this one policy.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Transparent description of data attrition, always-treated cohorts, and estimator limitations (Sections 2–3; p. 3–9).
- Correct awareness of TWFE pitfalls and use of Sun–Abraham (p. 8–12).
- Honest reporting of pretrend violation (p. 11–12), which many applied papers under-emphasize.

### Critical weaknesses
1. **Identification failure**: statistically significant pretrend and endogenous adoption; short pre-period; always-treated early adopters. Current estimates cannot support causal conclusions.
2. **Underdeveloped empirical content**: too few robustness checks, no category-specific mortality analysis, no monthly coding despite monthly data availability.
3. **Insufficient literature engagement**: missing key DiD methods (Callaway–Sant’Anna, de Chaisemartin–D’Haultfoeuille, BJS, Roth) and broader opioid policy/substitution literature.
4. **Format/length**: too short for a top general-interest journal; reads like a working paper memo rather than a complete journal article.

### Specific improvements (high priority)
- Rebuild around monthly data and precise implementation timing.
- Add alternative DiD estimators and stacked designs; provide decomposition of identifying variation.
- Report CIs prominently; upgrade inference (wild bootstrap).
- Expand outcome set to opioid subcategories.
- Substantially expand literature review and positioning.
- Reframe the paper’s main claim to match what the design can support.

---

DECISION: REJECT AND RESUBMIT